Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI Inc (NASDAQ: TEM) pioneers AI-driven healthcare solutions through its proprietary data integration platform. This news hub provides investors and healthcare professionals with essential updates on the company's technological advancements, strategic partnerships, and financial developments.
Access real-time announcements covering TEM's innovations in diagnostic analytics, generative AI applications, and healthcare data ecosystem expansions. Our curated collection includes earnings reports, regulatory filings, and analyses of platform enhancements that power precision medicine.
Key focus areas include AI-powered laboratory solutions, clinical research collaborations, and progress in breaking healthcare data silos. Stay informed about TEM's role in advancing personalized diagnostics through machine learning and large language model implementations.
Bookmark this page for verified updates on TEM's operational milestones, directly sourced from official communications. Monitor how the company continues redefining medical data utilization while maintaining HIPAA-compliant security standards across its platform.
Tempus AI (NASDAQ: TEM) and Genialis have announced a multi-year collaboration to develop new RNA-based algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate their AI foundation model, the Genialis™ Supermodel, which was developed using ~1 million RNA-sequencing samples.
Through this partnership, Genialis gains access to Tempus' Lens analytics platform, providing de-identified multimodal patient records to validate biomarker signatures. Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for their xR platform.
The collaboration has already yielded results with Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' data, effectively stratifies patients into response groups based on their likelihood of treatment success.
Tempus AI (NASDAQ: TEM) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025, in Boston, MA. The company's Chief Financial Officer, Jim Rogers, will engage in a fireside discussion on Monday, March 3. The event will be accessible to viewers through a live webcast.
Tempus, which specializes in leveraging artificial intelligence for precision medicine and patient care advancement, will use this platform to share insights about their technology and healthcare initiatives.
Ares Management (NYSE: ARES) has expanded its debt financing for Tempus AI (NASDAQ: TEM) with an additional $300 million, bringing the total debt package to $560 million. The new financing supports Tempus' recent acquisition of Ambry Genetics, which closed on February 3, 2025.
Tempus, founded in 2015, specializes in implementing AI solutions in healthcare, focusing on clinical care and research products. The company's integrated business model includes patient sequencing, data collection through licensing and analytical tools, and diagnostic testing insights across oncology, cardiology, pathology, and radiology.
This financing demonstrates Ares' capability to provide scalable capital to both non-sponsor-backed and sponsor-backed borrowers, with Ares expressing confidence in Tempus' growth strategy and the strategic acquisition of Ambry.
Tempus AI (NASDAQ: TEM) has announced its participation in the upcoming Morgan Stanley Technology, Media & Telecom Conference scheduled for March 3-6, 2025, in San Francisco, CA. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion on March 3, 2025. The event will be accessible to viewers through a live webcast.
Tempus, which specializes in leveraging AI technology for precision medicine and patient care advancement, will use this platform to share insights about their operations and innovations. This participation represents an important opportunity for investors and stakeholders to gain direct insights into the company's strategies and developments.
Tempus AI (NASDAQ: TEM) announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to develop a real-world multimodal, deidentified follicular lymphoma (FL) data library within Tempus' Lens platform. The initiative aims to accelerate the development of targeted therapies for FL patients through AI-driven insights.
The collaboration will initially focus on generating multimodal FL data for POD24 patients - those experiencing disease progression within 24 months of treatment - through a Tempus-sponsored study. The data library is expected to enhance researchers' understanding of FL biology and support the development of precision medicines by providing insights into the disease's heterogeneity.
The partnership combines IFLI's specialized FL focus with Tempus' AI-enabled solutions to create a centralized database that will be accessible to researchers and professionals working to combat follicular lymphoma.
Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its fourth quarter and full year 2024 financial results announcement for Monday, February 24, 2025. The earnings conference call will be held at 4:30 p.m. ET on the same day.
The call will feature presentations from CEO Eric Lefkofsky and CFO Jim Rogers. Investors can access the live audio webcast through Tempus' Investor Relations website's events page or join via phone using the provided domestic (888-596-4144) and international (646-968-2525) dial-in numbers with Conference ID: 9601821.
Tempus AI (NASDAQ: TEM) has completed its acquisition of Ambry Genetics, a genetic testing company focused on understanding genetics-disease relationships. The transaction, valued at $600 million total, consists of $375 million in cash and $225 million in shares, with $100 million subject to a one-year lock-up period. The acquisition was financed by Ares Management Credit funds.
Tempus CEO Eric Lefkofsky emphasized that this strategic acquisition enhances their capability to deliver advanced solutions to clinicians, patients, and life sciences companies by combining diagnostics and data. Ambry Genetics will continue operating as a wholly-owned subsidiary of Tempus, maintaining its current leadership team.
Genialis has extended its collaboration with Debiopharm to develop predictive biomarkers for WEE1-targeted therapy in cancer treatment. The partnership, building on a 2024 agreement, focuses on discovering biomarkers within the DNA damage response (DDR) biological space. Debiopharm's WEE1 asset is currently in Phase 1 clinical research.
The collaboration leverages the Genialis™ Supermodel, an AI-powered foundation model that enables rapid biomarker configuration across cancer drug targets. This technology, trained on hundreds of thousands of RNA-seq samples, helps stratify response groups and identify mechanisms of response and resistance.
The announcement follows Genialis' recent multi-year agreement with Tempus AI (NASDAQ: TEM) to validate RNA-based biomarker algorithms using Tempus' multimodal dataset. Genialis will present their findings at the 8th Annual DDR Inhibitors Summit and AACR Annual Meeting in 2025.
Tempus (NASDAQ: TEM) has announced the national launch of olivia, an AI-enabled personal health concierge app designed to centralize patient health data and make it actionable. The app connects to over 1,000 health systems through EHR integration and allows users to sync health device data or manually upload records.
Key features include: AI-generated smart profile summaries detailing clinical diagnoses and medications; AI-enabled notetaker for physician appointments; DICOM image sharing through a browser-native platform called pixel; health monitoring capabilities with Apple Health and Google Fit integration; and direct data import from healthcare providers.
The app organizes health information into a dynamic timeline, allowing patients to access records, lab results, and imaging reports. Users can query their health data using natural language, receiving AI-powered responses and insights. olivia is now available on both iOS and Android platforms.
Tempus AI (NASDAQ: TEM) has announced the nationwide launch of its FDA-approved xT CDx test, a comprehensive 648-gene next-generation sequencing test for solid tumor profiling. The test includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
The xT CDx employs a normal-matched approach, conducting parallel DNA sequencing of solid tumor and normal patient samples for more accurate identification of cancer-driving somatic variants. All existing tumor + normal match tests previously run on Tempus's signature xT assay will now be processed as xT CDx, maintaining the current ordering workflow.
Clinicians can enhance molecular insights by combining xT CDx with additional tests including xR RNA sequencing, xF/xF+ liquid biopsy, immunohistochemistry tests, and algorithmic tests for homologous recombination deficiency and immune profile scoring.
